Market Cap 10.76M
Revenue (ttm) 0.00
Net Income (ttm) -30.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 70,700
Avg Vol 184,766
Day's Range N/A - N/A
Shares Out 4.54M
Stochastic %K 84%
Beta 0.01
Analysts Strong Sell
Price Target $2.00

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 600 6438
Website: in8bio.com
Address:
350 5th Avenue, Suite 5330, New York, United States
INTELLECTUAL_NINJA
INTELLECTUAL_NINJA Aug. 15 at 1:36 AM
SELL $CAPR BUY $INAB
0 · Reply
INTELLECTUAL_NINJA
INTELLECTUAL_NINJA Aug. 15 at 1:31 AM
SELL $CAPR BUY $INAB
0 · Reply
INTELLECTUAL_NINJA
INTELLECTUAL_NINJA Aug. 15 at 1:30 AM
MALO has a new recommendation !!! I heard he is telling people to: SELL $CAPR BUY $INAB
2 · Reply
TheRealSixShifty
TheRealSixShifty Aug. 14 at 8:09 PM
$INAB Unloaded a few at 11% up. Holding a majority
0 · Reply
mikezdee
mikezdee Aug. 13 at 9:34 PM
$INAB 13/g filed
0 · Reply
dogood
dogood Aug. 12 at 12:16 PM
$FAMI when can we see double digits on these $FAMI $INAB $BINI $CLRB $TANH
0 · Reply
makedatbread88
makedatbread88 Aug. 8 at 6:40 PM
$INAB hmmmm ***Follow me for more winning calls***
0 · Reply
kshonstocks
kshonstocks Aug. 8 at 6:09 PM
alert hit $INAB off bottom play
1 · Reply
d_risk
d_risk Aug. 8 at 12:04 PM
$INAB - IN8BIO, INC. - 10Q - Updated Risk Factors INAB’s latest 10-Q risk factors spotlight Nasdaq listing and liquidity threats post-reverse split, severe going concern doubts, major financing and dilution risks, expanded clinical and manufacturing hurdles, new regulatory and IP uncertainties, a 49% workforce cut, and heightened exposure to stock volatility, compliance, and commercialization challenges. #Biotechnology #WorkforceReduction #ClinicalTrials #FinancingRisk #NasdaqListingRisk 🟢 Added 🟠 Removed https://d-risk.ai/INAB/10-Q/2025-08-07
1 · Reply
dogood
dogood Aug. 8 at 11:47 AM
$INAB come on guys send this to double digits
0 · Reply
Latest News on INAB
IN8bio to Present at Upcoming Investor Conferences

Feb 26, 2024, 8:00 AM EST - 1 year ago

IN8bio to Present at Upcoming Investor Conferences


IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Dec 7, 2023, 8:00 AM EST - 1 year ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors


INTELLECTUAL_NINJA
INTELLECTUAL_NINJA Aug. 15 at 1:36 AM
SELL $CAPR BUY $INAB
0 · Reply
INTELLECTUAL_NINJA
INTELLECTUAL_NINJA Aug. 15 at 1:31 AM
SELL $CAPR BUY $INAB
0 · Reply
INTELLECTUAL_NINJA
INTELLECTUAL_NINJA Aug. 15 at 1:30 AM
MALO has a new recommendation !!! I heard he is telling people to: SELL $CAPR BUY $INAB
2 · Reply
TheRealSixShifty
TheRealSixShifty Aug. 14 at 8:09 PM
$INAB Unloaded a few at 11% up. Holding a majority
0 · Reply
mikezdee
mikezdee Aug. 13 at 9:34 PM
$INAB 13/g filed
0 · Reply
dogood
dogood Aug. 12 at 12:16 PM
$FAMI when can we see double digits on these $FAMI $INAB $BINI $CLRB $TANH
0 · Reply
makedatbread88
makedatbread88 Aug. 8 at 6:40 PM
$INAB hmmmm ***Follow me for more winning calls***
0 · Reply
kshonstocks
kshonstocks Aug. 8 at 6:09 PM
alert hit $INAB off bottom play
1 · Reply
d_risk
d_risk Aug. 8 at 12:04 PM
$INAB - IN8BIO, INC. - 10Q - Updated Risk Factors INAB’s latest 10-Q risk factors spotlight Nasdaq listing and liquidity threats post-reverse split, severe going concern doubts, major financing and dilution risks, expanded clinical and manufacturing hurdles, new regulatory and IP uncertainties, a 49% workforce cut, and heightened exposure to stock volatility, compliance, and commercialization challenges. #Biotechnology #WorkforceReduction #ClinicalTrials #FinancingRisk #NasdaqListingRisk 🟢 Added 🟠 Removed https://d-risk.ai/INAB/10-Q/2025-08-07
1 · Reply
dogood
dogood Aug. 8 at 11:47 AM
$INAB come on guys send this to double digits
0 · Reply
RealityTrumpsDelusion
RealityTrumpsDelusion Aug. 8 at 12:32 AM
$INAB Unfortunately, by the end of February 2026, they'll be out of cash.
1 · Reply
RealityTrumpsDelusion
RealityTrumpsDelusion Aug. 8 at 12:22 AM
$INAB Liquidity and Going Concern - To date, the Company has funded its operations primarily with proceeds from various public and private offerings of its common stock, preferred stock and warrants. The Company has incurred recurring losses and negative operating cash flows since its inception, including net losses of $10.6 million and $17.2 million for the six months ended June 30, 2025 and 2024, respectively. As of June 30, 2025, the Company had an accumulated deficit of $132.3 million.
0 · Reply
RealityTrumpsDelusion
RealityTrumpsDelusion Aug. 8 at 12:21 AM
$INAB Liquidity and Going Concern - We continue to deploy cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility given the ongoing market environment for biotechnology stocks. These cash preservation measures may impact our ability and the timing to execute our strategy. This includes our ability to achieve the anticipated milestones and the timing of data releases and/or regulatory filings for our preclinical and clinical programs.
0 · Reply
RealityTrumpsDelusion
RealityTrumpsDelusion Aug. 8 at 12:19 AM
$INAB Liquidity and Going Concern - The Company has not yet generated product sales and as a result has experienced operating losses since inception. The Company expects to incur additional losses in the future as it advances its product candidates through clinical trials, seeks to expand its product candidate portfolio through developing additional product candidates, grows its clinical, regulatory and quality capabilities, and incurs costs associated with operating as a public company.
0 · Reply
RealityTrumpsDelusion
RealityTrumpsDelusion Aug. 8 at 12:17 AM
$INAB Liquidity and Going Concern - The actual amount of cash that the Company will need to operate is subject to many factors. Based on the Company’s revised business strategy, which was announced in September 2024, its existing cash of $13.2 million as of June 30, 2025 is not anticipated to fund the Company’s projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern.
0 · Reply
mikezdee
mikezdee Aug. 7 at 10:17 PM
$INAB financials released
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Aug. 7 at 9:04 PM
$INAB So we are trading well below cash value
0 · Reply